Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review

Authors: Alessandro Mantovani, Christopher D Byrne, Giovanni Targher - The Lancet 2022 cited by 207